THE ELITE UNIVERSAL
TEST BANK: WOMEN'S
HEALTH PRIMARY CARE
(5TH EDITION)
PART 0: THE NAVIGATOR
● PART I: THE PRIMER
○ The Clinical Hook
○ The "Critical Axioms" Cheat Sheet
○ The 2026/2027 Clinical Landscape (Narrative & Structured Data)
● PART II: THE ELITE TEST BANK
○ Tier 1 (Questions 1–28) - Foundational Syntax & Application: Testing "Hard
Deck" definitions, screening algorithms (Cervical, Breast, Bone), and pharmacologic
dosing protocols.
○ Tier 2 (Questions 29–58) - Complex Application & Simulation: Cross-pathology
presentations, STI syndromic management, AUB interventions, and Menopause
(VMS) hormone therapy matching.
○ Tier 3 (Questions 59–88) - Grandmaster Synthesis: Multi-variant
obstetric/postpartum crises, WPATH SOC 8 integration, APCM billing alignment,
and cardiometabolic syndrome mitigation.
PART I: THE PRIMER
The mastery of women's primary care is the dividing line between algorithmic compliance and
the elite optimization of female longevity, reproductive autonomy, and complex chronic disease
management. This document forges practitioners who do not merely follow guidelines, but
anticipate physiologic trajectories to avert systemic morbidity.
● The 2026 hrHPV Directive: Primary high-risk HPV testing every 5 years (with a
self-collection option) is the unequivocally preferred cervical screening modality for
average-risk individuals aged 30-65.
● The AMH Diagnostic Shift: Elevated Anti-Müllerian Hormone (AMH) replaces
ultrasonography for detecting polycystic ovarian morphology in adults, fundamentally
altering PCOS diagnostics.
● The Endometriosis Empiric Mandate: The 2026 ACOG guidelines authorize the
immediate initiation of empiric medical therapy based purely on a clinical diagnosis of
cyclic pelvic pain, rendering the "diagnostic laparoscopy" obsolete as a prerequisite for
, care.
● The Postpartum Cardiovascular Link: Gestational hypertension and preeclampsia are
not isolated obstetric events; they are profound cardiometabolic stress tests requiring
immediate postpartum blood pressure surveillance and lifelong AHA/ACC risk
stratification using the PREVENT-ASCVD equations.
● The AUB PALM-COEIN Standard: Immediate stabilization of acute Abnormal Uterine
Bleeding utilizes multi-dose combined oral contraceptives or high-dose tranexamic acid,
followed by structural categorization via the PALM-COEIN framework.
The 2026/2027 Clinical Landscape: A Narrative Synthesis
The landscape of women's health primary care has undergone a radical transformation, moving
away from reactive, fragmented treatments toward a proactive, integrated, and highly
personalized approach. Evidence-based guidelines from authoritative bodies such as ACOG,
the CDC, and the USPSTF have iteratively adapted to real-world clinical barriers, technological
advancements, and a deeper understanding of health inequities. For the elite practitioner,
mastering this evolution is non-negotiable.
A central theme in recent updates is the dismantling of historical barriers to care through the
empowerment of patient autonomy and the optimization of non-invasive diagnostics. For
instance, the Health Resources and Services Administration (HRSA) 2026 updates have
formally positioned patient-collected high-risk human papillomavirus (hrHPV) testing as a
preferred modality for cervical cancer screening in average-risk women aged 30 to 65. This
eliminates the speculum exam as a barrier for trauma survivors and marginalized populations.
Concurrently, the American College of Obstetricians and Gynecologists (ACOG) has overhauled
the approach to endometriosis, explicitly recommending empiric medical treatment based on
clinical symptoms and transvaginal ultrasonography, thereby attacking the nine-year diagnostic
delay caused by the legacy reliance on surgical laparoscopy. Furthermore, the diagnosis of
Polycystic Ovary Syndrome (PCOS) now integrates serum Anti-Müllerian Hormone (AMH)
levels as a surrogate for polycystic ovarian morphology in adults, providing a highly specific,
accessible biomarker that bypasses the subjectivity of transabdominal or transvaginal imaging.
Beyond reproductive endocrinology, the management of cardiovascular and metabolic risk
remains the cornerstone of female longevity. The AHA/ACC 2025/2026 guidelines have
transitioned away from the Pooled Cohort Equations, mandating the use of the
PREVENT-ASCVD tool to capture a broader spectrum of cardiovascular-kidney-metabolic risks.
This is particularly critical in the postpartum window; conditions like preeclampsia are now
universally recognized as early indicators of lifelong cardiovascular disease. Consequently,
ACOG's tailored prenatal care model emphasizes early screening for social drivers of health
(SDOH) before ten weeks of gestation, replacing the rigid 14-visit schedule with individualized,
tele-health-supported care pathways.
In behavioral health, the integration of mental health surveillance into primary care has been
codified. The utilization of the EPDS-US screening tool addresses cultural nuances previously
missed by legacy depression scales. To sustain this integrated care model financially, the
Centers for Medicare & Medicaid Services (CMS) introduced the Advanced Primary Care
Management (APCM) G-codes in 2026. These risk-stratified codes (G0556, G0557, G0558)
eliminate arbitrary time-tracking in favor of holistic outcome management, supported by add-on
codes (G0568) specifically designed to reimburse psychiatric collaborative care within the
primary care setting.
,Clinical Domain 2026/2027 Advanced Standard Replaced Legacy Protocol
Cervical Cancer Primary hrHPV testing every 5 Cytology alone or mandatory
years (self-collection option) speculum exams
PCOS Diagnosis Serum AMH evaluation + Strict reliance on Transvaginal
Clinical/Biochemical Ultrasound (AFC)
Hyperandrogenism
Endometriosis Empiric suppression based on Mandatory diagnostic
clinical symptoms & TVUS laparoscopy
Breast Density Mandatory FDA notification; Vague reporting; reliance on 2D
supplemental MRI/MBI mammography alone
discussion
STI Treatment Doxycycline 100mg BID x 7 Single-dose Azithromycin 1g
days for Chlamydia; Doxy PEP
APCM Billing Code Target Population & Criteria 2026 Reimbursement
Framework
G0556 Zero or one chronic illness; Value-based, replacing
staff-led coordination minimum minute requirements
G0557 Two or more chronic conditions Escalated reimbursement for
expected to last \ge 12 months complex multi-morbidity
G0568 Initial psychiatric collaborative Add-on code allowing seamless
care management behavioral integration
PART II: THE ELITE TEST BANK
Tier 1: Foundational Syntax & Application
Q1: Under the 2026 HRSA/WPSI guidelines, a 35-year-old average-risk female requires cervical
cancer screening. Which testing modality is the PREFERRED primary approach? A) Cervical
cytology alone every 3 years B) Cytology and hrHPV co-testing every 3 years C) Primary hrHPV
testing every 5 years, offering patient self-collection D) Annual pelvic examination with Pap
smear
● The Answer: C (Primary hrHPV testing every 5 years, offering patient self-collection)
● Distractor Analysis:
○ A is incorrect: Cytology alone is now a secondary contingency if hrHPV testing is
unavailable.
○ B is incorrect: Co-testing is acceptable every 5 years, not 3, and is no longer the
solitary preferred method.
○ D is incorrect: Annual screening leads to overtreatment of transient viral clearance.
The Mentor's Analysis: The 2026 paradigm shifts from cellular morphology to viral etiology. By
utilizing patient-collected hrHPV, you eliminate trauma and access barriers.
Professional/Academic Intuition: Always default to primary hrHPV testing every 5 years for
average-risk patients aged 30-65.
Q2: According to the 2023/2026 International Evidence-based Guidelines, which biomarker is
now formally incorporated as an alternative to ultrasonography for diagnosing Polycystic Ovary
Syndrome (PCOS) in adults? A) Serum CA-125 B) Anti-Müllerian Hormone (AMH) C) Sex
Hormone Binding Globulin (SHBG) D) Fasting insulin
, ● The Answer: B (Anti-Müllerian Hormone (AMH))
● Distractor Analysis:
○ A is incorrect: CA-125 is an ovarian malignancy marker, explicitly discouraged in
PCOS.
○ C is incorrect: SHBG is suppressed in hyperandrogenism but is not a standalone
diagnostic criterion.
○ D is incorrect: Insulin resistance is a consequence of PCOS, not a primary
diagnostic criterion.
The Mentor's Analysis: AMH directly reflects the antral follicle count. By measuring AMH,
clinicians bypass the invasiveness of transvaginal ultrasonography in adults.
Professional/Academic Intuition: Elevated AMH confirms polycystic ovarian morphology in
adults, but MUST NOT be used in adolescents due to physiological peaks.
Q3: Following the FDA Mammography Quality Standards Act update, a patient's report states:
"The breasts are heterogeneously dense." What is the IMMEDIATE required clinical action? A)
Refer for prophylactic bilateral mastectomy. B) Provide the FDA-mandated dense breast
notification and discuss supplemental imaging. C) Order a genetic BRCA panel. D) Downgrade
their routine screening to every 3 years.
● The Answer: B (Provide the FDA-mandated dense breast notification and discuss
supplemental imaging.)
● Distractor Analysis:
○ A is incorrect: Density alone is not an indication for surgical prophylaxis.
○ C is incorrect: Genetic testing requires familial or specific histological risk factors,
not merely density.
○ D is incorrect: Dense breasts obscure lesions and raise baseline risk, requiring
maintained or escalated screening.
The Mentor's Analysis: Dense tissue both masks malignancies and acts as an independent
oncologic risk factor. Integrating molecular breast imaging or MRI is vital. Professional/Academic
Intuition: Density notification is federally mandated; individualized supplemental imaging
discussion is a clinical imperative.
Q4: A 66-year-old female undergoes her first DXA scan. Her T-score is -2.6 at the femoral neck.
What is the MOST ACCURATE diagnostic classification? A) Osteopenia B) Normal bone density
for age C) Osteoporosis D) Severe Paget's disease
● The Answer: C (Osteoporosis)
● Distractor Analysis:
○ A is incorrect: Osteopenia is strictly defined by a T-score between -1.0 and -2.4.
○ B is incorrect: A T-score of -2.6 indicates profound bone loss compared to peak
adult mass.
○ D is incorrect: Paget's requires distinct radiographic and alkaline phosphatase
findings.
The Mentor's Analysis: The World Health Organization's hard deck for osteoporosis is a T-score
of -2.5 or lower. Professional/Academic Intuition: A T-score of -2.5 or below is diagnostic for
osteoporosis and unequivocally mandates pharmacologic intervention.
Q5: Under ACOG's Abnormal Uterine Bleeding (AUB) guidelines, which classification system
MUST be used to categorize the structural versus non-structural etiology of the bleeding? A)
BI-RADS B) FRAX C) PALM-COEIN D) Rotterdam Criteria
● The Answer: C (PALM-COEIN)
● Distractor Analysis:
○ A is incorrect: BI-RADS is utilized exclusively for breast imaging.
TEST BANK: WOMEN'S
HEALTH PRIMARY CARE
(5TH EDITION)
PART 0: THE NAVIGATOR
● PART I: THE PRIMER
○ The Clinical Hook
○ The "Critical Axioms" Cheat Sheet
○ The 2026/2027 Clinical Landscape (Narrative & Structured Data)
● PART II: THE ELITE TEST BANK
○ Tier 1 (Questions 1–28) - Foundational Syntax & Application: Testing "Hard
Deck" definitions, screening algorithms (Cervical, Breast, Bone), and pharmacologic
dosing protocols.
○ Tier 2 (Questions 29–58) - Complex Application & Simulation: Cross-pathology
presentations, STI syndromic management, AUB interventions, and Menopause
(VMS) hormone therapy matching.
○ Tier 3 (Questions 59–88) - Grandmaster Synthesis: Multi-variant
obstetric/postpartum crises, WPATH SOC 8 integration, APCM billing alignment,
and cardiometabolic syndrome mitigation.
PART I: THE PRIMER
The mastery of women's primary care is the dividing line between algorithmic compliance and
the elite optimization of female longevity, reproductive autonomy, and complex chronic disease
management. This document forges practitioners who do not merely follow guidelines, but
anticipate physiologic trajectories to avert systemic morbidity.
● The 2026 hrHPV Directive: Primary high-risk HPV testing every 5 years (with a
self-collection option) is the unequivocally preferred cervical screening modality for
average-risk individuals aged 30-65.
● The AMH Diagnostic Shift: Elevated Anti-Müllerian Hormone (AMH) replaces
ultrasonography for detecting polycystic ovarian morphology in adults, fundamentally
altering PCOS diagnostics.
● The Endometriosis Empiric Mandate: The 2026 ACOG guidelines authorize the
immediate initiation of empiric medical therapy based purely on a clinical diagnosis of
cyclic pelvic pain, rendering the "diagnostic laparoscopy" obsolete as a prerequisite for
, care.
● The Postpartum Cardiovascular Link: Gestational hypertension and preeclampsia are
not isolated obstetric events; they are profound cardiometabolic stress tests requiring
immediate postpartum blood pressure surveillance and lifelong AHA/ACC risk
stratification using the PREVENT-ASCVD equations.
● The AUB PALM-COEIN Standard: Immediate stabilization of acute Abnormal Uterine
Bleeding utilizes multi-dose combined oral contraceptives or high-dose tranexamic acid,
followed by structural categorization via the PALM-COEIN framework.
The 2026/2027 Clinical Landscape: A Narrative Synthesis
The landscape of women's health primary care has undergone a radical transformation, moving
away from reactive, fragmented treatments toward a proactive, integrated, and highly
personalized approach. Evidence-based guidelines from authoritative bodies such as ACOG,
the CDC, and the USPSTF have iteratively adapted to real-world clinical barriers, technological
advancements, and a deeper understanding of health inequities. For the elite practitioner,
mastering this evolution is non-negotiable.
A central theme in recent updates is the dismantling of historical barriers to care through the
empowerment of patient autonomy and the optimization of non-invasive diagnostics. For
instance, the Health Resources and Services Administration (HRSA) 2026 updates have
formally positioned patient-collected high-risk human papillomavirus (hrHPV) testing as a
preferred modality for cervical cancer screening in average-risk women aged 30 to 65. This
eliminates the speculum exam as a barrier for trauma survivors and marginalized populations.
Concurrently, the American College of Obstetricians and Gynecologists (ACOG) has overhauled
the approach to endometriosis, explicitly recommending empiric medical treatment based on
clinical symptoms and transvaginal ultrasonography, thereby attacking the nine-year diagnostic
delay caused by the legacy reliance on surgical laparoscopy. Furthermore, the diagnosis of
Polycystic Ovary Syndrome (PCOS) now integrates serum Anti-Müllerian Hormone (AMH)
levels as a surrogate for polycystic ovarian morphology in adults, providing a highly specific,
accessible biomarker that bypasses the subjectivity of transabdominal or transvaginal imaging.
Beyond reproductive endocrinology, the management of cardiovascular and metabolic risk
remains the cornerstone of female longevity. The AHA/ACC 2025/2026 guidelines have
transitioned away from the Pooled Cohort Equations, mandating the use of the
PREVENT-ASCVD tool to capture a broader spectrum of cardiovascular-kidney-metabolic risks.
This is particularly critical in the postpartum window; conditions like preeclampsia are now
universally recognized as early indicators of lifelong cardiovascular disease. Consequently,
ACOG's tailored prenatal care model emphasizes early screening for social drivers of health
(SDOH) before ten weeks of gestation, replacing the rigid 14-visit schedule with individualized,
tele-health-supported care pathways.
In behavioral health, the integration of mental health surveillance into primary care has been
codified. The utilization of the EPDS-US screening tool addresses cultural nuances previously
missed by legacy depression scales. To sustain this integrated care model financially, the
Centers for Medicare & Medicaid Services (CMS) introduced the Advanced Primary Care
Management (APCM) G-codes in 2026. These risk-stratified codes (G0556, G0557, G0558)
eliminate arbitrary time-tracking in favor of holistic outcome management, supported by add-on
codes (G0568) specifically designed to reimburse psychiatric collaborative care within the
primary care setting.
,Clinical Domain 2026/2027 Advanced Standard Replaced Legacy Protocol
Cervical Cancer Primary hrHPV testing every 5 Cytology alone or mandatory
years (self-collection option) speculum exams
PCOS Diagnosis Serum AMH evaluation + Strict reliance on Transvaginal
Clinical/Biochemical Ultrasound (AFC)
Hyperandrogenism
Endometriosis Empiric suppression based on Mandatory diagnostic
clinical symptoms & TVUS laparoscopy
Breast Density Mandatory FDA notification; Vague reporting; reliance on 2D
supplemental MRI/MBI mammography alone
discussion
STI Treatment Doxycycline 100mg BID x 7 Single-dose Azithromycin 1g
days for Chlamydia; Doxy PEP
APCM Billing Code Target Population & Criteria 2026 Reimbursement
Framework
G0556 Zero or one chronic illness; Value-based, replacing
staff-led coordination minimum minute requirements
G0557 Two or more chronic conditions Escalated reimbursement for
expected to last \ge 12 months complex multi-morbidity
G0568 Initial psychiatric collaborative Add-on code allowing seamless
care management behavioral integration
PART II: THE ELITE TEST BANK
Tier 1: Foundational Syntax & Application
Q1: Under the 2026 HRSA/WPSI guidelines, a 35-year-old average-risk female requires cervical
cancer screening. Which testing modality is the PREFERRED primary approach? A) Cervical
cytology alone every 3 years B) Cytology and hrHPV co-testing every 3 years C) Primary hrHPV
testing every 5 years, offering patient self-collection D) Annual pelvic examination with Pap
smear
● The Answer: C (Primary hrHPV testing every 5 years, offering patient self-collection)
● Distractor Analysis:
○ A is incorrect: Cytology alone is now a secondary contingency if hrHPV testing is
unavailable.
○ B is incorrect: Co-testing is acceptable every 5 years, not 3, and is no longer the
solitary preferred method.
○ D is incorrect: Annual screening leads to overtreatment of transient viral clearance.
The Mentor's Analysis: The 2026 paradigm shifts from cellular morphology to viral etiology. By
utilizing patient-collected hrHPV, you eliminate trauma and access barriers.
Professional/Academic Intuition: Always default to primary hrHPV testing every 5 years for
average-risk patients aged 30-65.
Q2: According to the 2023/2026 International Evidence-based Guidelines, which biomarker is
now formally incorporated as an alternative to ultrasonography for diagnosing Polycystic Ovary
Syndrome (PCOS) in adults? A) Serum CA-125 B) Anti-Müllerian Hormone (AMH) C) Sex
Hormone Binding Globulin (SHBG) D) Fasting insulin
, ● The Answer: B (Anti-Müllerian Hormone (AMH))
● Distractor Analysis:
○ A is incorrect: CA-125 is an ovarian malignancy marker, explicitly discouraged in
PCOS.
○ C is incorrect: SHBG is suppressed in hyperandrogenism but is not a standalone
diagnostic criterion.
○ D is incorrect: Insulin resistance is a consequence of PCOS, not a primary
diagnostic criterion.
The Mentor's Analysis: AMH directly reflects the antral follicle count. By measuring AMH,
clinicians bypass the invasiveness of transvaginal ultrasonography in adults.
Professional/Academic Intuition: Elevated AMH confirms polycystic ovarian morphology in
adults, but MUST NOT be used in adolescents due to physiological peaks.
Q3: Following the FDA Mammography Quality Standards Act update, a patient's report states:
"The breasts are heterogeneously dense." What is the IMMEDIATE required clinical action? A)
Refer for prophylactic bilateral mastectomy. B) Provide the FDA-mandated dense breast
notification and discuss supplemental imaging. C) Order a genetic BRCA panel. D) Downgrade
their routine screening to every 3 years.
● The Answer: B (Provide the FDA-mandated dense breast notification and discuss
supplemental imaging.)
● Distractor Analysis:
○ A is incorrect: Density alone is not an indication for surgical prophylaxis.
○ C is incorrect: Genetic testing requires familial or specific histological risk factors,
not merely density.
○ D is incorrect: Dense breasts obscure lesions and raise baseline risk, requiring
maintained or escalated screening.
The Mentor's Analysis: Dense tissue both masks malignancies and acts as an independent
oncologic risk factor. Integrating molecular breast imaging or MRI is vital. Professional/Academic
Intuition: Density notification is federally mandated; individualized supplemental imaging
discussion is a clinical imperative.
Q4: A 66-year-old female undergoes her first DXA scan. Her T-score is -2.6 at the femoral neck.
What is the MOST ACCURATE diagnostic classification? A) Osteopenia B) Normal bone density
for age C) Osteoporosis D) Severe Paget's disease
● The Answer: C (Osteoporosis)
● Distractor Analysis:
○ A is incorrect: Osteopenia is strictly defined by a T-score between -1.0 and -2.4.
○ B is incorrect: A T-score of -2.6 indicates profound bone loss compared to peak
adult mass.
○ D is incorrect: Paget's requires distinct radiographic and alkaline phosphatase
findings.
The Mentor's Analysis: The World Health Organization's hard deck for osteoporosis is a T-score
of -2.5 or lower. Professional/Academic Intuition: A T-score of -2.5 or below is diagnostic for
osteoporosis and unequivocally mandates pharmacologic intervention.
Q5: Under ACOG's Abnormal Uterine Bleeding (AUB) guidelines, which classification system
MUST be used to categorize the structural versus non-structural etiology of the bleeding? A)
BI-RADS B) FRAX C) PALM-COEIN D) Rotterdam Criteria
● The Answer: C (PALM-COEIN)
● Distractor Analysis:
○ A is incorrect: BI-RADS is utilized exclusively for breast imaging.
